Physician profile
Hannah Webber
NPI 1902460231
$2,106.50
in general payments reported to CMS, 2019-2025
25 companies · $758 in 2025
The $758 reported for 2025 was more than what 81% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12.19 · 2020: $18.39 · 2022: $15.49 · 2023: $155 · 2024: $1,147 · 2025: $758.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,060.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,060.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $543.25 | 2023-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $338.88 | 2023-2025 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $211.69 | 2024-2025 | Evenity, Prolia, Repatha |
| Biogen, INC. | $126.61 | 2024-2025 | Skyclarys |
| Bayer Healthcare Pharmaceuticals INC. | $118.61 | 2023-2025 | |
| Pfizer INC. | $106.77 | 2023-2025 | |
| Abbvie INC. | $70.56 | 2023-2025 | Vraylar |
| Novo Nordisk INC | $67.80 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Janssen Pharmaceuticals, INC | $62.19 | 2024-2025 | Spravato |
| Xeris Pharmaceuticals, INC. | $58.91 | 2023-2025 | Keveyis, Gvoke Hypopen |
| Boehringer Ingelheim Pharmaceuticals, INC. | $57.74 | 2024-2025 | Jardiance, Spiriva Respimat |
| Tris Pharma INC | $54.02 | 2024 | Dyanavel Xr |
| Exact Sciences Corporation | $49.15 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $30.57 | 2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $26.63 | 2024 | Abilify Maintena |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $23.53 | 2024 | Dexcom G6 Transmitter |
| Procept Biorobotics Corporation | $21.59 | 2025 | |
| Lundbeck LLC | $21.49 | 2024 | Vyepti |
| Lexicon Pharmaceuticals, INC. | $19.86 | 2024 | |
| Aimmune Therapeutics, INC. | $18.80 | 2024 | |
| Akorn, INC. | $18.39 | 2020 | |
| Novartis Pharmaceuticals Corporation | $18.10 | 2024 | |
| Alkermes, INC. | $15.49 | 2022 | |
| Optinose US, INC. | $13.68 | 2025 | |
| Merck Sharp & Dohme LLC | $12.19 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hannah Webber listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.